PARIS, November 30, 2023 /PRNewswire/ — Unither Pharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO), is celebrating 30 years in business. In 1993, Unither Pharmaceuticals began operations by acquiring a 17-person pharmaceutical factory that produced 3 pharmaceutical forms. Today, the company is a world leader in the manufacturing of sterile unit doses, with a production capacity of 5 billion doses and a presence on four continents. This growth is also reflected in an increase in sales, which are expected to reach 500 million euros by 2023.
To view the multimedia press release, please click on:
https://www.multivu.com/players/uk/9229051-unither-pharmaceuticals-celebrates-30-years-innovation-expertise/
Unither first implemented Blow-Fill-Seal (BFS) technology in 1995, allowing it to manufacture sterile doses of saline solutions, asthma medications and eye drops. From 1997, the company developed its international activity, first by exporting its products, then by acquiring a factory in United States in 2013. With the acquisition of Barretos in 2015, Unither gained a foothold in Brazil. Then in 2020, an acquisition in China, in Nanjing, has consolidated its global presence. In 2022, Unither will further expand its activities with the acquisition of a new site specializing in ophthalmology in São Paulo. This international development aims to support the international industrial strategies of its clients by getting closer to their target markets.
Since its inception, Unither has been at the forefront of innovation, continually striving to improve patients’ lives. Eric GoupilPresident of Unither Pharmaceuticals, recalls the group’s vision: “We want to be recognized for making health solutions accessible to as many people as possible that improve and simplify patients’ lives. We imagine new ideas, and our enthusiasm and energy allow us to make them come true. them for the benefit of our customers.”
Jean-François Hilaire, CEO of Unither Pharmaceuticals, looks to the future: “Unither’s mission is to support our customers in their process of innovation and in their efforts to meet the demands of their markets. With Euroject®, our recent advancement in merging a single-use dose with a needle to create a ready-to-use injection system, illustrates Unither’s commitment to simplifying the lives of healthcare professionals and patients. patients, while controlling costs.”
About Unither Pharmaceuticals: www.unither-pharma.com/about/who-are-we/
Press contact:
contact@unither-pharma.com
Video – https://www.youtube.com/watch?v=lNCXXx_8wTo
SOURCE Unither Pharmaceuticals
